Sanofi (ENXTPA:SAN) Stops Amlitelimab In Eczema And Expands Aqemia AI Pact

negativeAmlitelimabNegative

AI Analysis

Summary

Sanofi has discontinued development of amlitelimab for eczema while simultaneously expanding its partnership with AI company Aqemia. The decision to stop the eczema program represents a setback for the therapeutic candidate.

Outcome Details

Development stopped

Importance:4/10

Sentiment:

-0.60

program_terminationeczemapartnershipAI

Related Companies

$SNY

Read the original article

Published by yahoo_finance on July 25, 2026 12:16 AM

Read Original